Published in Cancer Res on April 14, 2009
Nonlinear modelling of cancer: bridging the gap between cells and tumours. Nonlinearity (2010) 2.08
Multiscale cancer modeling. Annu Rev Biomed Eng (2011) 1.65
What does physics have to do with cancer? Nat Rev Cancer (2011) 1.59
Three-dimensional multispecies nonlinear tumor growth-II: Tumor invasion and angiogenesis. J Theor Biol (2010) 1.37
Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail? Curr Gene Ther (2009) 1.33
Modeling evolutionary dynamics of epigenetic mutations in hierarchically organized tumors. PLoS Comput Biol (2011) 1.18
Solving the puzzle of metastasis: the evolution of cell migration in neoplasms. PLoS One (2011) 1.12
Physical oncology: a bench-to-bedside quantitative and predictive approach. Cancer Res (2011) 0.98
Parameterizing the Logistic Model of Tumor Growth by DW-MRI and DCE-MRI Data to Predict Treatment Response and Changes in Breast Cancer Cellularity during Neoadjuvant Chemotherapy. Transl Oncol (2013) 0.97
Modeling the mechanics of cancer: effect of changes in cellular and extra-cellular mechanical properties. Front Oncol (2013) 0.94
Mathematical Oncology: How Are the Mathematical and Physical Sciences Contributing to the War on Breast Cancer? Curr Breast Cancer Rep (2010) 0.88
Integrative physical oncology. Wiley Interdiscip Rev Syst Biol Med (2011) 0.88
An integrated computational/experimental model of lymphoma growth. PLoS Comput Biol (2013) 0.87
Computational models of VEGF-associated angiogenic processes in cancer. Math Med Biol (2011) 0.87
Systems biology and physiome projects. Wiley Interdiscip Rev Syst Biol Med (2010) 0.86
Predictions of tumour morphological stability and evaluation against experimental observations. J R Soc Interface (2010) 0.84
The effects of cell compressibility, motility and contact inhibition on the growth of tumor cell clusters using the Cellular Potts Model. J Theor Biol (2013) 0.83
An Adaptive Multigrid Algorithm for Simulating Solid Tumor Growth Using Mixture Models. Math Comput Model (2011) 0.82
Morphology of melanocytic lesions in situ. Sci Rep (2014) 0.81
Modeling the connection between primary and metastatic tumors. J Math Biol (2012) 0.79
A stable scheme for a nonlinear, multiphase tumor growth model with an elastic membrane. Int J Numer Method Biomed Eng (2014) 0.79
Influence of the microenvironment on cell fate determination and migration. Physiol Genomics (2014) 0.78
Accurate state estimation from uncertain data and models: an application of data assimilation to mathematical models of human brain tumors. Biol Direct (2011) 0.77
The Clinical Significance and Molecular Features of the Spatial Tumor Shapes in Breast Cancers. PLoS One (2015) 0.75
Applications of a new In vivo tumor spheroid based shell-less chorioallantoic membrane 3-D model in bioengineering research. J Biomed Sci Eng (2010) 0.75
Tissue-scale, personalized modeling and simulation of prostate cancer growth. Proc Natl Acad Sci U S A (2016) 0.75
Mathematical modelling of spatio-temporal glioma evolution. Theor Biol Med Model (2013) 0.75
Model of Vascular Desmoplastic Multispecies Tumor Growth. J Theor Biol (2017) 0.75
Experimental method and statistical analysis to fit tumor growth model using SPECT/CT imaging: a preclinical study. Quant Imaging Med Surg (2017) 0.75
Model on cell movement, growth, differentiation and de-differentiation: reaction-diffusion equation and wave propagation. Eur Phys J E Soft Matter (2013) 0.75
Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer (2005) 13.49
Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer (2003) 13.01
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med (2001) 10.37
Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer (2005) 8.70
Malignant glioma: genetics and biology of a grave matter. Genes Dev (2001) 6.78
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell (2003) 6.59
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A (1994) 5.44
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia (2001) 4.22
Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol (1999) 4.15
Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell (2006) 4.07
Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res (2001) 3.21
'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol (2006) 2.37
Genes and pathways driving glioblastomas in humans and murine disease models. Neurosurg Rev (2003) 2.32
Integrative mathematical oncology. Nat Rev Cancer (2008) 2.28
Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res (2002) 2.23
A history of the study of solid tumour growth: the contribution of mathematical modelling. Bull Math Biol (2004) 2.21
Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A (1998) 2.15
An integrated computational/experimental model of tumor invasion. Cancer Res (2006) 1.93
A mathematical model of glioblastoma tumor spheroid invasion in a three-dimensional in vitro experiment. Biophys J (2006) 1.91
Nonlinear simulation of tumor necrosis, neo-vascularization and tissue invasion via an adaptive finite-element/level-set method. Bull Math Biol (2005) 1.91
Computer simulation of glioma growth and morphology. Neuroimage (2007) 1.83
Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci U S A (2003) 1.79
Nonlinear simulation of tumor growth. J Math Biol (2003) 1.72
Targeting the tumor microenvironment. Front Biosci (2007) 1.72
Development of a three-dimensional multiscale agent-based tumor model: simulating gene-protein interaction profiles, cell phenotypes and multicellular patterns in brain cancer. J Theor Biol (2006) 1.66
The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol (2003) 1.63
Angiogenesis in malignant gliomas. Glia (1995) 1.62
Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir Suppl (2003) 1.59
Three-dimensional multispecies nonlinear tumor growth--I Model and numerical method. J Theor Biol (2008) 1.57
Nonlinear simulation of the effect of microenvironment on tumor growth. J Theor Biol (2006) 1.56
Morphologic instability and cancer invasion. Clin Cancer Res (2005) 1.55
Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas. Cancer Res (2003) 1.53
Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. J Math Biol (2008) 1.48
Modelling aspects of cancer dynamics: a review. Philos Trans A Math Phys Eng Sci (2006) 1.48
Predictive oncology: a review of multidisciplinary, multiscale in silico modeling linking phenotype, morphology and growth. Neuroimage (2007) 1.39
Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev Anticancer Ther (2006) 1.30
The effects of EGF-receptor density on multiscale tumor growth patterns. J Theor Biol (2005) 1.25
Hypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures. Neurosurg Focus (2006) 1.18
Biological mechanisms of glioma invasion and potential therapeutic targets. J Neurooncol (2001) 1.18
Nonlinear simulations of solid tumor growth using a mixture model: invasion and branching. J Math Biol (2008) 1.13
Classification of glioblastoma multiforme in adults by molecular genetics. Cancer J (2003) 0.99
Vascularity and angiogenesis as predictors of growth in optic pathway/hypothalamic gliomas. J Neurosurg (2006) 0.96
Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma. Clin Cancer Res (2004) 0.90
Metastases and their microenvironments: linking pathogenesis and therapy. Drug Resist Updat (2005) 0.84
Photodynamic therapy of newly implanted glioma cells in the rat brain. Lasers Surg Med (2006) 0.82
A cross-platform toolkit for mass spectrometry and proteomics. Nat Biotechnol (2012) 4.48
Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol (2008) 3.78
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res (2002) 3.72
Intravascular delivery of particulate systems: does geometry really matter? Pharm Res (2008) 3.13
Clinical proteomics: written in blood. Nature (2003) 2.81
Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. Nat Cell Biol (2008) 2.81
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl (2009) 2.74
Nanotechnologies for biomolecular detection and medical diagnostics. Curr Opin Chem Biol (2006) 2.74
Seven challenges for nanomedicine. Nat Nanotechnol (2008) 2.59
Whole chromosome instability caused by Bub1 insufficiency drives tumorigenesis through tumor suppressor gene loss of heterozygosity. Cancer Cell (2009) 2.58
Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res (2010) 2.41
Focal adhesion kinase is required for blood vessel morphogenesis. Circ Res (2003) 2.18
Multiscale modelling and nonlinear simulation of vascular tumour growth. J Math Biol (2008) 2.18
Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol (2010) 2.17
Patient-calibrated agent-based modelling of ductal carcinoma in situ (DCIS): from microscopic measurements to macroscopic predictions of clinical progression. J Theor Biol (2012) 2.00
Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem (2010) 1.97
An integrated computational/experimental model of tumor invasion. Cancer Res (2006) 1.93
Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol (2012) 1.85
Design of microfluidic channel geometries for the control of droplet volume, chemical concentration, and sorting. Lab Chip (2004) 1.85
Computer simulation of glioma growth and morphology. Neuroimage (2007) 1.83
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res (2003) 1.81
Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials (2007) 1.72
Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J Control Release (2011) 1.72
Tailored porous silicon microparticles: fabrication and properties. Chemphyschem (2010) 1.71
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows. Nanotechnology (2009) 1.63
The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials (2009) 1.63
What does physics have to do with cancer? Nat Rev Cancer (2011) 1.59
Morphologic instability and cancer invasion. Clin Cancer Res (2005) 1.55
Nanogeometry: beyond drug delivery. Nat Nanotechnol (2008) 1.54
Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res (2009) 1.53
Precursor-ion mass re-estimation improves peptide identification on hybrid instruments. J Proteome Res (2008) 1.53
Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One (2010) 1.49
Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. J Math Biol (2008) 1.48
Osmotic pressure beyond concentration restrictions. J Phys Chem B (2007) 1.46
Biotechnology apprenticeship for secondary-level students: teaching advanced cell culture techniques for research. Cell Biol Educ (2002) 1.45
Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res (2011) 1.45
Hesperetin impairs glucose uptake and inhibits proliferation of breast cancer cells. Cell Biochem Funct (2012) 1.44
Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. Cancer Res (2009) 1.39
Predictive oncology: a review of multidisciplinary, multiscale in silico modeling linking phenotype, morphology and growth. Neuroimage (2007) 1.39
A New Ghost Cell/Level Set Method for Moving Boundary Problems: Application to Tumor Growth. J Sci Comput (2008) 1.39
Cdc20 hypomorphic mice fail to counteract de novo synthesis of cyclin B1 in mitosis. J Cell Biol (2010) 1.38
Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther (2009) 1.38
Three-dimensional multispecies nonlinear tumor growth-II: Tumor invasion and angiogenesis. J Theor Biol (2010) 1.37
T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci U S A (2003) 1.37
Antibiological barrier nanovector technology for cancer applications. Expert Opin Drug Deliv (2007) 1.36
Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Adv (2012) 1.35
Mitotic trafficking of silicon microparticles. Nanoscale (2009) 1.35
Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice. Adv Funct Mater (2012) 1.35
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
Cellular association and assembly of a multistage delivery system. Small (2010) 1.32
Biodegradable porous silicon barcode nanowires with defined geometry. Adv Funct Mater (2010) 1.31
Dynamics of multicomponent vesicles in a viscous fluid. J Comput Phys (2010) 1.31
Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. J Biomed Mater Res A (2010) 1.31
Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev Anticancer Ther (2006) 1.30
Enabling individualized therapy through nanotechnology. Pharmacol Res (2010) 1.28
Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci (2011) 1.27
Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest (2014) 1.26
The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems. J Theor Biol (2012) 1.25
The preferential targeting of the diseased microvasculature by disk-like particles. Biomaterials (2012) 1.25
Interstitial stress and fluid pressure within a growing tumor. Ann Biomed Eng (2003) 1.25
Cyclic stretch induced miR-146a upregulation delays C2C12 myogenic differentiation through inhibition of Numb. Biochem Biophys Res Commun (2008) 1.23
Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta (2010) 1.23
Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci (2010) 1.22
Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res (2013) 1.21
Logic-embedded vectors for intracellular partitioning, endosomal escape, and exocytosis of nanoparticles. Small (2010) 1.19
Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting. PLoS One (2010) 1.19
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res (2002) 1.19
CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate (2004) 1.18
Selection in spatial stochastic models of cancer: migration as a key modulator of fitness. Biol Direct (2010) 1.17
Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv Healthc Mater (2011) 1.16
Quantitative mechanics of endothelial phagocytosis of silicon microparticles. Cytometry A (2009) 1.16
Tailoring of the nanotexture of mesoporous silica films and their functionalized derivatives for selectively harvesting low molecular weight protein. ACS Nano (2010) 1.16
Design of bio-mimetic particles with enhanced vascular interaction. J Biomech (2009) 1.15
Intracellular trafficking of silicon particles and logic-embedded vectors. Nanoscale (2010) 1.15
HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res (2010) 1.13
Laparoscopic treatment of splenic artery aneurysms. J Vasc Surg (2009) 1.13
Nonlinear simulations of solid tumor growth using a mixture model: invasion and branching. J Math Biol (2008) 1.13
E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow. Adv Mater (2011) 1.12
TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene (2002) 1.12
2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer (2005) 1.12